Estrella Immunopharma Reports $2.3 Million Net Loss and Increased Operating Expenses for Q1 2026

Estrella Immunopharma, Inc. reported a net loss of approximately $2.3 million for the three months ended March 31, 2026, compared to a net loss of $2.1 million for the same period in 2025. The company's total operating expenses increased to $2.3 million from $2.1 million year-over-year, primarily driven by higher general and administrative costs, which rose by 28.5% to $891,789. Research and development expenses remained relatively stable at approximately $1.4 million, reflecting ongoing costs associated with the STARLIGHT-1 clinical trial for its lead product candidate, EB103.

The company’s financial position showed improvement, with total assets increasing to $3.7 million as of March 31, 2026, up from $3.2 million at the end of 2025. Cash and cash equivalents also rose to $1.9 million from $1.4 million. However, Estrella continues to face significant liabilities, totaling approximately $8.9 million, leading to a stockholders' deficit of $5.3 million. The increase in cash was attributed to a registered direct offering completed in January 2026, which generated gross proceeds of approximately $8.0 million.

Strategically, Estrella has made notable advancements in its clinical programs. The company completed Phase I dosing for the STARLIGHT-1 trial in November 2025 and has dosed ten patients as of March 31, 2026. The company is also actively working with Eureka Therapeutics under a Services Agreement, which includes a Statement of Work for clinical trial services. As of the reporting date, Estrella has accrued approximately $8.3 million in liabilities related to milestone payments owed to Eureka.

Looking ahead, Estrella Immunopharma anticipates that its expenses will continue to rise as it advances its clinical trials and seeks regulatory approvals for its product candidates. The company has expressed concerns regarding its ability to continue as a going concern, citing recurring losses and the need for additional financing to support its operations. Management has indicated that while recent financing efforts have provided some liquidity, there is substantial doubt about the company's ability to meet its working capital requirements in the near future without further capital raises.